Gupta N, et al. - In this two-part, phase I study, researchers determined the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. As per observations, a treatment-emergent adverse event was evident in all patients, which most commonly involved the gastrointestinal system. Findings suggested that ixazomib was extensively metabolized, with urine representing the predominant route of excretion of drug-related material.